1. Runx3 combined deletion in DCs and thymocytes fully recapitulates Runx3-null tumor resistance.
Runx3 combined deletion in DCs and thymocytes fully recapitulates Runx3-null tumor resistance. A, Runx3 ablation in CD8+ T cells. Western blot analysis (left) of sorted splenic CD8+ T cells from WT and TRunx3−/− mice. Note the Runx1 expression in cells from both genotypes. Right, decreased tumor multiplicity and delayed onset in TRunx3−/− (n = 12), compared with WT littermate mice (n = 28). B, detection of morphologically sound DETCs in naïve epidermis of TRunx3−/− and WT littermate mice. Anti-CD3e-FITC immunostained epidermal sheets (scale bars, 100 and 20 μm in ×100 and ×630, respectively). See also Supplementary Fig. S3. C, DCRunx3−/−/TRunx3−/− mice exhibit resistance to DMBA/TPA tumorigenesis, similar to that noted in Runx3-null mice. Reduced yield and delayed onset of papillomas in DCRunx3−/−/TRunx3−/− mice (n = 9), compared with controls (n = 21). Values in A and C are mean ± SD.
Omri Bauer et al. Cancer Prev Res 2014;7:
©2014 by American Association for Cancer Research